Abstract: Methods for treating or preventing ulcers caused by Epidermolysis Bullosa (“EB”), EGFR inhibitor-induced skin toxicities, lesions caused by Hailey-Hailey Disease (“HHD”), Buruli Ulcers, and SARS-CoV-2 infections, by topically applying a hypotonic, acid oxidizing solution containing hypochlorous acid (HClO) to the affected area.

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 170 of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: The present invention relates to methods of treating or preventing an infection or infectious disease in a mammal, or sanitizing mammalian tissue, or treating or preventing psoriasis in a mammal, comprising topically administering to said mammal an electrolytic acid water comprising free chlorine, wherein: a) from 90% to 99.9% of said free chlorine is present in the form of hypochlorous acid; b) said water has a pH of from 0.5 to 5.0; and c) said water has oxidation reduction potential (ORP) of greater than 1100 mV. The present invention also relates to methods of healing, repair or regeneration of a tissue in a mammal comprising topically administering to said tissue said electrolytic acid water.

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 170 of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: The present invention relates to a method of treating an outer eye disorder selected from a cataract, neovascularization, keratitis, epithelium deficiency, or chronic opacity, by administering to the eye a composition comprising acidic electrolytic water. The present invention also relates to a stable acidic electrolyzed oxidizing water characterized by low conductivity, the presence of dissolved chlorine gas (Cl2), hypochlorous acid (HOCl) and chloride ions (Cl?), and by the presence of negligible quantities of hypochlorite ion (OCl?).

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: The present invention relates to a method of treating an outer eye disorder selected from a cataract, neovascularization, keratitis, epithelium deficiency, or chronic opacity, by administering to the eye a composition comprising acidic electrolytic water. The present invention also relates to a stable acidic electrolyzed oxidizing water characterized by low conductivity, the presence of dissolved chlorine gas (Cl2), hypochlorous acid (HOCl) and chloride ions (Cl?), and by the presence of negligible quantities of hypochlorite ion (OCl?).

Abstract: The present invention relates to methods of treating or preventing an infection or infectious disease in a mammal, or sanitizing mammalian tissue, or treating or preventing psoriasis in a mammal, comprising topically administering to said mammal an electrolytic acid water comprising free chlorine, wherein: a) from 90% to 99.9% of said free chlorine is present in the form of hypochlorous acid; b) said water has a pH of from 0.5 to 5.0; and c) said water has oxidation reduction potential (ORP) of greater than 1100 mV. The present invention also relates to methods of healing, repair or regeneration of a tissue in a mammal comprising topically administering to said tissue said electrolytic acid water.

Abstract: The present invention relates to methods of treating or preventing an infection or infectious disease in a mammal, or sanitizing mammalian tissue, or treating or preventing psoriasis in a mammal, comprising topically administering to said mammal an electrolytic acid water comprising free chlorine, wherein: a) from 90% to 99.9% of said free chlorine is present in the form of hypochlorous acid; b) said water has a pH of from 0.5 to 5.0; and c) said water has oxidation reduction potential (ORP) of greater than 1100 mV. The present invention also relates to methods of healing, repair or regeneration of a tissue in a mammal comprising topically administering to said tissue said electrolytic acid water.

Abstract: A highly stable aqueous solution having a molecular cluster with dimensions which are small enough to ensure substantial chemical-physical stability thereof for a relatively long time. To prepare the solution a fluid treatment device is used, which comprises at least one chamber (7) and at least one anode (4) and one cathode (3) arranged in the chamber (7). The anode (4) and cathode (3) are at least partly made of a first metallic material. At least one of the at least one cathode (3) and anode (4) comprises a coating of nanoparticles (5) of a second metallic material.

Abstract: The present invention relates to methods of treating or preventing an infection or infectious disease in a mammal, or sanitizing mammalian tissue, or treating or preventing psoriasis in a mammal, comprising topically administering to said mammal an electrolytic acid water comprising free chlorine, wherein: a) from 90% to 99.9% of said free chlorine is present in the form of hypochlorous acid; b) said water has a pH of from 0.5 to 5.0; and c) said water has oxidation reduction potential (ORP) of greater than 1100 mV. The present invention also relates to methods of healing, repair or regeneration of a tissue in a mammal comprising topically administering to said tissue said electrolytic acid water.

Abstract: The present invention relates to a method of treating an outer eye disorder selected from a cataract, neovascularization, keratitis, epithelium deficiency, or chronic opacity, by administering to the eye a composition comprising acidic electrolytic water. The present invention also relates to a stable acidic electrolyzed oxidizing water characterized by low conductivity, the presence of dissolved chlorine gas (Cl2), hypochlorous acid (HOCl) and chloride ions (Cl?), and by the presence of negligible quantities of hypochlorite ion (OCl?).

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: A highly stable aqueous solution having a molecular cluster with dimensions which are small enough to ensure substantial chemical-physical stability thereof for a relatively long time. To prepare the solution a fluid treatment device is used, which comprises at least one chamber (7) and at least one anode (4) and one cathode (3) arranged in the chamber (7). The anode (4) and cathode (3) are at least partly made of a first metallic material. At least one of the at least one cathode (3) and anode (4) comprises a coating of nanoparticles (5) of a second metallic material.